Jade Biosciences (JBIO) Return on Capital Employed (2021 - 2026)
Jade Biosciences (JBIO) posted Return on Capital Employed of 42.78% for Q1 2026, up 2.2% on a QoQ basis from 43.74% in Q4 2025, and up 9556.0% year-over-year from 0.44% in Q1 2025.
Jade Biosciences (JBIO) Return on Capital Employed (2021 - 2026) Analysis & Trends
Jade Biosciences' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 42.78% for Q1 2026.
- Quarterly Return on Capital Employed rose 9556.0% year-over-year to 42.78% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 42.78% (up 9556.0% YoY) and the FY2025 annual result came in at 58.3%, up 2636.0% from the prior year.
- Return on Capital Employed was 42.78% for Q1 2026 at Jade Biosciences, up from 43.74% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 18.78% in Q1 2022 and bottomed at 145.78% in Q4 2024.
- A 5-year average of 67.07% and a median of 56.29% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed plunged 7591 bps — and 2025, when it soared 10204 bps.
- Jade Biosciences' Return on Capital Employed stood at 39.82% in 2022, then tumbled by 75 bps to 69.87% in 2023, then slumped by 109 bps to 145.78% in 2024, then surged by 70 bps to 43.74% in 2025, then increased by 2 bps to 42.78% in 2026.
- Business Quant data shows JBIO's Return on Capital Employed at 42.78% in Q1 2026, 43.74% in Q4 2025, and 59.79% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Jade Biosciences | 16.25 Mn | 16.25 Mn | - | -42.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.78% |
| Dec 31, 2025 | -43.74% |
| Sep 30, 2025 | -59.79% |
| Jun 30, 2025 | -79.19% |
| Mar 31, 2025 | -138.34% |
| Dec 31, 2024 | -145.78% |
| Sep 30, 2024 | -97.13% |
| Jun 30, 2024 | -102.15% |
| Mar 31, 2024 | -86.99% |
| Dec 31, 2023 | -69.87% |
| Sep 30, 2023 | -56.29% |
| Jun 30, 2023 | -53.62% |
| Mar 31, 2023 | -50.21% |
| Dec 31, 2022 | -39.82% |
| Sep 30, 2022 | -31.71% |
| Jun 30, 2022 | -23.92% |
| Mar 31, 2022 | -18.78% |
| Dec 31, 2021 | -12.99% |
| Sep 30, 2021 | -15.42% |